Monoclonal Antibody (mAb) Infusion at UVA COVID-19 Clinic

**Referring Patients for Monoclonal Antibody (mAb) Infusion Therapy**
mAb Infusion therapy is offered in the UVA COVID-19 Clinic under FDA Emergency Use Authorization (EUA). All referrals for Monoclonal Antibody (mAb) Infusion therapy require approval and referral using the below process:

1. **Complete patient information, eligibility, and risk sections of the referral form.**
2. **Request approval.** Call the UVA hospital operator at 434.924.0000 and ask for the “COVID-19 MD” provider to be paged at PIC #9007 to review patient information and obtain approval.
3. **Complete and submit.** Once approved, this referral form may be faxed to the UVA COVID-19 Clinic at 434.243.9800.

The COVID clinic infusion team will review the referral, and contact the patient to coordinate services.

**Access and Cost Considerations:**

* Initial supplies of these two mAb products will be allocated in limited quantities by the Virginia Department of Health. Demand is expected to exceed supply. Based on the individual patient’s clinical factors and the mAbs supply, patients are scheduled according to the individual’s clinical factors in consultation with our Infectious Disease experts. Given the limited doses available, it is possible that some referrals may not be able to be accommodated.
* While there is no cost for the medication itself, charges related to clinic care and drug preparation/administration may apply. Financial assistance is available to those eligible-both insured and uninsured-to minimize any direct cost to patients. In short, financial concerns should not be a barrier to patient access.

**Learn more:**

[**Patient and Provider Education**](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs)

**Professional Guidance:**

* Infectious Diseases Society of America [guideline statement of bamlanivimab](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-11).
* NIH COVID-19 treatment guideline panel statements on [bamlanivimab](https://www.covid19treatmentguidelines.nih.gov/statement-on-bamlanivimab-eua)and [casirivimab/imdevimab](https://www.covid19treatmentguidelines.nih.gov/statement-on-casirivimab-plus-imdevimab-eua).
* FDA Emergency Use Authorization: <https://www.fda.gov/media/143892/download>.